Urodynamix closes $1.5 million non-brokered private placement for common shares

Urodynamix Technologies Ltd. (TSX VENTURE:URO) is pleased to announce that it has closed a $1.5 million non-brokered private placement for 30,000,000 common shares previously reported on September 11, 2009. BC Advantage Funds (VCC) Ltd. subscribed for $750,000 and management and directors subscribed for $238,675 of the $1.5 million placement.

The Company will offer an additional 10,000,000 common shares to third parties at a price of $0.05. No commission was payable on the 15,000,000 common shares issued to BC Advantage Funds under the first closing of the private placement. The Company will pay a commission of up to 7.5% on sales of common shares to third parties. All of the common shares issued under the private placement are subject to a four month resale restriction.

http://www.mdxmedical.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.